Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 2/20 | 0.34 |
| ▸ | CDK8 | P49336 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337943 | 1.00 | TRPA1 (0.40) | TRPA1FFAR2NR3C2THRBALOX12 | |
| SCHEMBL4510283 | 0.85 | GSK3B (0.40) | TRPA1FFAR2NR3C2MAOAMAOB | |
| SCHEMBL4521461 | 0.83 | FFAR2 (0.38) | TRPA1FFAR2KMT2AMAOAMAOB | |
| SCHEMBL4521465 | 0.83 | FFAR2 (0.38) | TRPA1FFAR2KMT2AMAOAMAOB | |
| SCHEMBL4521278 | 0.81 | FFAR2 (0.36) | TRPA1FFAR2MAOAMAOBMAPT | |
| SCHEMBL4521277 | 0.81 | FFAR2 (0.36) | TRPA1FFAR2MAOAMAOBMAPT | |
| SCHEMBL4092908 | 0.77 | FFAR2 (0.42) | TRPA1FFAR2THRBALOX12KMT2A | |
| SCHEMBL4097126 | 0.77 | FFAR2 (0.43) | TRPA1FFAR2KMT2AMAOAMAOB | |
| SCHEMBL4087306 | 0.75 | FFAR2 (0.34) | TRPA1FFAR2MAOAMAOBMAPT | |
| SCHEMBL4089653 | 0.75 | FFAR2 (0.34) | TRPA1FFAR2MAOAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | TRPA1 169/4885FFAR2 2407/4885NR3C2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.